Table 3. Clinical findings of the patient and control groups.
| Patient group (n=40) | Control group (n=40) | ||||||||
| n | % | Median | Min-Max | n | % | Median | Min-Max | p | |
| Previous bone fracture | 2 | 5.0 | 2 | 5.0 | 1.000 | ||||
| Musculoskeletal pain | 38 | 95.0 | 25 | 62.5 | <0.001 | ||||
| Proximal muscle weakness | 9 | 22.5 | 1 | 2.5 | 0.007 | ||||
| Abnormal walking gait | 3 | 7.5 | 1 | 2.5 | 0.615 | ||||
| Periarticular sensitivity | 26 | 5.0 | 9 | 22.5 | <0.001 | ||||
| Visual analog scale score | 6 | 0-10 | 5 | 0-8 | 0.004 | ||||
| Beck Depression Inventory score | 0.375 | ||||||||
| Normal | 12 | 30.0 | 19 | 47.5 | |||||
| Mild | 13 | 32.5 | 11 | 27.5 | |||||
| Moderate | 12 | 30.0 | 9 | 22.5 | |||||
| Severe | 3 | 7.5 | 1 | 2.5 | |||||
| Short Form 36 | |||||||||
| Physical component summary | 37 | 20-57 | 32 | 16-61 | 0.419 | ||||
| Mental component summary | 42 | 14-56 | 44 | 25-59 | 0.633 | ||||
| Min: Minimum; Max: Maximum; Patient group: Serum 25(OH)D3 level <25 ng/mL; Control group: Serum 25(OH)D3 level ≥25 ng/mL. | |||||||||